RBC Capital downgraded Spruce Biosciences to Sector Perform from Outperform with a price target of $2, down from $9. The company reported a CAHmelia-203 topline miss, with tildacerfont failing to achieve the primary endpoint, the analyst tells investors in a research note. The firm cites new program doubts and the company’s extended timeline uncertainty for the downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRB:
- SPRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Three new option listings on February 27th
- Spruce Biosciences price target raised to $9 from $8 at RBC Capital
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim
